
|Videos|June 4, 2021
Dr. Grünwald on depth of response and efficacy with pembrolizumab/lenvatinib in renal cell carcinoma
Author(s)Urology Times staff
Advertisement
The phase 3 CLEAR trial showed that frontline therapy with pembrolizumab (Keytruda) plus lenvatinib (Lenvima) reduced the risk of death by 34% versus sunitinib (Sutent) in patients with advanced renal cell carcinoma.
In this video, Viktor Grünwald, MD, University Hospital Essen, Germany, discusses an analysis shared at the 2021 ASCO Annual Meeting which explored efficacy in the CLEAR trial according to selected subgroups, as well as the association between depth of response and overall survival. (J Clin Oncol 39, 2021 [suppl 15; abstr 4560])
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
Datopotamab deruxtecan enters phase 3 trial in high-risk muscle-invasive urothelial cancer
2
Pearls & Perspectives: From Emergency Medicine to Sexual Medicine, With Jeff Myers, DO
3
Nicole L. Miller, MD, FACS, on persistent LUTS after BPH treatment
4
AI system links surgical gestures with postoperative outcomes
5












